AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright

Stock News

2025/09/01

H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a "Buy" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.

Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1183251394"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183251394\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183251394?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183251394","market":"sg","top_or_hot":-1,"title":"AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright","media":"Stock News","content":"<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO's Innovative Drug Benefits Drive Partner Summit Therapeutics (SMMT.US) Target Price Upgrade to $50 by H.C. Wainwright\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-01 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.</p>\n<p>Summit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348783233.USD","symbol_name":"安联东方收入型 CI A Dis美元","start_time":0,"source_url":"","article_id":"1183251394","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183251394","pubTimestamp":1756707626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","LU0348783233.USD":"安联东方收入型 CI A Dis美元","BK1161":"生物科技","BK1574":"生物医药B类股","BK4139":"生物科技","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","06978":"永泰生物-B","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","SMMT":"Summit Therapeutics PLC"},"translate_title":"康方生物的创新药物优势促使合作伙伴Summit Therapeutics(SMMT.US)H.C.将目标价上调至50美元。温赖特","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"SMMT":1,"09926":1,"06978":1},"content_text":"H.C. Wainwright has released a research report raising Summit Therapeutics Inc. (SMMT.US) target price from $44 to $50 while maintaining a \"Buy\" rating. The firm indicated to investors that AKESO's ivonescimab Phase III HARMONi-A study data has validated Chinese clinical results, demonstrating superior efficacy compared to Keytruda. The report also emphasized that now presents an opportune time to position in Summit, given its unique advantages as AKESO's collaboration partner in the US market.\nSummit is a biopharmaceutical company dedicated to developing and commercializing innovative therapies addressing severe unmet medical needs. The company's products focus on delivering benefits to patients, families, physicians, and society, aiming to extend life and improve quality of life. Summit's current clinical development programs are primarily concentrated in the Clostridioides difficile infection (CDI) therapeutic area.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}